TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
Manage episode 347166835 series 3381434
Creato da ReachMD, autore scoperto da Player FM e dalla nostra community - Il copyright è detenuto dall'editore, non da Player FM, e l'audio viene riprodotto direttamente dal suo server. Clicca sul pulsante Iscriviti per rimanere aggiornato su Player FM, o incolla l'URL del feed in un altra app per i podcast.
CME credits: 0.50
Valid until: 15-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/trop2-adcs-for-metastatic-nsclc-setting-the-stage-for-future-use/14416/
Antibody-drug conjugates (ADCs) have promising clinical data in the treatment of advanced non-small cell lung cancer. Listen in as Drs. Benjamin Levy, Rebecca Heist, and Peter Illei discuss current data on TROP2 ADCs and what this means for our patients.=
Valid until: 15-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/trop2-adcs-for-metastatic-nsclc-setting-the-stage-for-future-use/14416/
Antibody-drug conjugates (ADCs) have promising clinical data in the treatment of advanced non-small cell lung cancer. Listen in as Drs. Benjamin Levy, Rebecca Heist, and Peter Illei discuss current data on TROP2 ADCs and what this means for our patients.=
847 episodi
))
